Company Overview - Adagio Medical Holdings, Inc. is a medical device company based in Laguna Hills, California, specializing in catheter ablation technologies for treating cardiac arrhythmias [4] - The company focuses on developing and commercializing its proprietary Ultra-Low Temperature Cardiac (ULTA) ablation technology, which aims to create large, durable lesions in both diseased and healthy cardiac tissue [4] Recent Developments - The company will present live at the Small Cap Growth Virtual Investor Conference on February 5, 2026, allowing real-time interaction with investors [1] - Adagio has appointed Sean Salmon, a former Senior Executive from Medtronic, to its Board of Directors [8] - The company closed financing of up to $50 million, led by existing and new healthcare-dedicated institutional investors [8] Clinical Trials - Adagio's vCLAS™ Cryoablation System is currently under evaluation in the FULCRUM-VT U.S. Pivotal IDE Trial, which has fully enrolled 209 patients with structural heart disease [5] - The FULCRUM-VT trial aims to assess the feasibility of ultra-low temperature cryoablation for recurring monomorphic ventricular tachycardia and will be used to apply for FDA premarket approval [5] - Preliminary results from the FULCRUM-VT study indicate a 97% acute effectiveness rate and favorable safety profile [8] Product Availability - The vCLAS™ Cryoablation System is commercially available for treating monomorphic ventricular tachycardia in Europe and select other regions, but is limited to investigational use in the United States [5]
Adagio Medical to Present at the Small Cap Growth Virtual Investor Conference February 5th